Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.43 |
| ▸ | RARG | P13631 | 5/20 | 0.43 |
| ▸ | RARA | P10276 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 3/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | HNF4A | P41235 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9006914 | 0.88 | RARB (0.35) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL4373360 | 0.81 | RARB (0.45) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8081759 | 0.81 | RARB (0.45) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL9188117 | 0.81 | RARB (0.48) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL6668910 | 0.78 | RARA (0.45) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL7560489 | 0.77 | RXRA (0.50) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL3456678 | 0.77 | RARB (0.51) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL9190581 | 0.77 | RARB (0.53) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL10557225 | 0.77 | RARB (0.44) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8562770 | 0.76 | AKR1B1 (0.34) | AKR1B1SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | claimed |
| US-20070238881-A1 | Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-10-11 | — | — | US | claimed |
| WO-2006059345-A2 | PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-06-08 | — | — | WO | claimed |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-05-18 | — | — | US | claimed |
| WO-2005123713-A1 | PROCESS FOR THE PREPARATION OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-12-29 | — | — | WO | claimed |
| US-6963002-B2 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-11-08 | — | — | US | claimed |
| WO-2005003125-A1 | PROCESS FOR THE PREPARATION OF 4,4-DIMETHYL-6-ETHYNYLTHIOCHROMAN | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-01-13 | — | — | WO | claimed |
| US-20050004373-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | GLENMARK GENERICS LTD. (IN) | 2005-01-06 | — | — | US | claimed |
| US-20200216407-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-09 | — | — | US | disclosed |
| US-10556879-B2 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADMENY OF SCIENCES (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2019-03-28 | — | — | US | disclosed |
| EP-3428155-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2019-01-16 | — | — | EP | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-5053523-A | Chemical intermediate for compounds having retinoic acid-like activity | ALLERGAN, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-5023341-A | Acetylene thiochroman | ALLERGAN, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0419132-A2 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| US-4810804-A | PSORIASIS | ALLERGAN, INC. (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0290130-A1 | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid like activity | ALLERGAN, INC (US) | 1988-11-09 | — | — | EP | disclosed |
| EP-0284288-A1 | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238881-A1 | Process for the preparation of tazarotene intermediates and use thereof for the preparation of tazarotene | NAMPT, NAPRT, NNT | RARB 2078/4885RARG 2738/4885RARA 1989/4885 |
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | PPIA, CUTA, TFPI | RARB 130/4885RARG 294/4885RARA 77/4885 |
| US-20050004373-A1 | Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman | YAP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA | RARB 1135/4885RARG 1336/4885RARA 1124/4885 |
| US-10556879-B2 | Retinoid compound, preparation method therefor, intermediates thereof and application thereof | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
| US-20060106233-A1 | Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups | CBR3, NR1H2, NR3C2 | RARB 2140/4885RARG 2656/4885RARA 2569/4885 |
| US-20200216407-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.